Genomics to fight cancer

• El Bachir Affar
  • New Gene Targets for Personalized Medicine in Sarcoma
• Upton Allen
  • Genomic Evidence for Precision Medicine for Selected Chronic Diseases among Black Peoples in Canada
• Mark Basik
  • Developing a personalized plasma-based approach for the detection of minimal residual disease in breast cancer
• Mathieu Blanchette
  • Deciphering mechanisms of epigenetic alterations in cancer using 3D-genomics-informed deep learning
• Christopher H. Borchers
  • Developing the Next Generation PD-L1 Assays Using Precision Mass Spectrometry
  • Second generation diagnostics: iMALDI-based assays for protein activity to improve patient selection for therapeutic Akt inhibitors in cancer treatment
  • MutaQuant: A powerful proteogenomic phenotyping tool for precision medicine
• Mathias Cavaillé
  • Integration of the polygenic risk score in the management of women at moderate genetic or familial risk of breast cancer
• Sonia Cellot
  • Delivering precision medicine in pediatric hemato-oncology by integrating clinical genomics into the care pathway
• Jacques Drouin
  • Decoding the cancer epigenome with novel AI discovery tools
• Amin Emad
  • AI models to predict response to drug combinations in poor outcome cancer patients
• Humphrey Fonge
  • Enhancing immunotherapy in small cell lung cancer with a therapeutic radiopharmaceutical
• Lucy Gilbert
  • Detecting Ovarian and Endometrial Cancer Early Using Genomics (DOvEEgene)
• Aline Hajj
  • A Risk Prediction Tool for Chemotherapy-Induced Painful Peripheral Neuropathy
• Nada Jabado
  • Tackling childhood brain cancer at the root to improve survival and quality of life
• David Juncker
  • Single exosome multi-omic analysis
  • Digital Omics of Single Exosomes
• Vincent-Philippe Lavallé
  • Sensitive and Non-Invasive Approaches for Precision Diagnosis in Pediatric Oncology
• Frédéric Leblond
  • Machine learning technology applied to the discovery of new vibrational spectroscopy biomarkers for the prognostication of intermediate-risk prostate cancer patients
• Sébastien Lemieux
  • Deep learning for precision medicine by joint analysis of gene expression profiles measured through RNA-Seq and microarrays
  • Novel dimensionality reduction approaches for vector-based representations of expression profiles and chemical compounds to assist in the development of acute myeloid leukemia therapies
• Emanuelle Lemyre
  • Detecting chromosome anomalies in pediatric leukemia using new DNA analysis technology
• Éric Massé
  • Using the gut microbiome as biomarker for colorectal cancer screening in Québec
• Anne-Marie Mes-Masson
  • Targeting genomic instability as a key vulnerability in ovarian cancer
• Peter Metrakos
  • Liquid biopsy to detect and monitor minimal residual disease in patients with colorectal cancer liver metastasis
• Hermann Nabi
  • Chemotherapy or No Chemotherapy after Breast Surgery?
• Morag Park
  • Targeted vulnerabilities to overcome drug resistance in breast cancer
  • MISO CHIP Microfluidic Platform: A new physiologically relevant preclinical ex vivo 3D metastatic tumor model for biomarker development and personalized medicine
• Dea A. Regier
  • Canadian Network for Learning Healthcare Systems and Cost-Effective ‘Omics Innovation (CLEO)
• Guy Sauvageau
  • Interrogating and implementing Omics for precision medicine in acute myeloid leukemia
  • Development of a Novel Cyclin K Degrader of High-risk AML Patients and Associated Genomic Features
• Sachdev Sidhu
  • Synthetic inhibitors of ubiquitin-binding cancer targets
• Peter Siegel
  • Towards single-cell metabolomics: uncovering the metabolic heterogeneity and architecture of solid cancers
• Jacques Simard
  • Personalized risk assessment for prevention and early detection of breast cancer: Integration and Implementation
• Martin Smith
  • Nanopores and precision medicine: A quasi-instantaneous diagnosis to accelerate leukemia patient management
• Lee Hwa-Tai
  • Therapeutic bacteria programmed to eliminate tumours
• Pierre Thibault
  • Bridging the ProteoGenomics Gap for Personalized Medicine Using Transformative Mass Spectrometry Technologies
  • Matching MHC I-associated peptide spectra to sequencing reads using deep neural networks
• Michel L. Tremblay
  • Establishing therapeutic cord blood-derived NK cells for hard-to-treat cancers through omics based and pharmacological activators
• Dominique Trudel
  • Putting Together the Puzzle Pieces: A Path to Precision Medicine
• Ian Watson
  • MELANO-PREDICT: development of a clinically applicable algorithm for prediction of checkpoint inhibitor response in melanoma
  • Montreal Cancer Consortium
• Brian Wilhelm
  • Establishing a chemogenomic screening pipeline for high-risk pediatric leukemias
  • Using chemogenomic data to improve drug predictions based on machine learning

For several years, Génome Québec has collaborated with Génome Canada and several other key partners in the field to accelerate cancer research:

4 universities and 8 hospitals and their affiliated research institutes active in Québec

48 teams mobilized

Among recent strategic partnerships:

• Funding in partnership with the Quebec Breast Cancer Foundation

In 2025, Génome Québec and the Quebec Breast Cancer Foundation announced their partnership to fund the validation of a genetic analysis tool enabling personalized breast cancer screening based on each woman’s individual risk. To learn more about this funding: A new solution to detect breast cancer

• Operating grants in partnership with the Cancer Research Society

In 2020, Génome Québec teamed up with the Cancer Research Society to fund four operating grants totaling $480,000.

• Omics Data Against Cancer (ODAC) Competition

In 2020, Génome Québec, IVADO, and Oncopole joined forces to launch the ODAC competition, aiming to promote multidisciplinary research in artificial intelligence, omics sciences, and oncology. This partnership supported the development of AI applications and tools capable of leveraging cancer research datasets. To learn more about the results of this partnership: Artificial Intelligence

Multi-Institutional Teams Against Cancer (EMC²) Competition

In 2018, Génome Québec, Oncopole, the Cancer Research Society, and IRICoR joined forces to fund the Multi-institutional Cancer Teams (EMC2) competition. This competition aimed to fund large-scale, structured research projects that leveraged existing networks, platforms, resources, expertise, and strengths in Québec.

Montreal Cancer Consortium (MCC)

In 2018, Génome Québec announced its support for the launch of the Montreal Cancer Consortium (MCC), funded by the Terry Fox Research Institute under the Marathon of Hope Cancer Centres Network Pilots program. To learn more about this partnership: Génome Québec supports Montreal Cancer Consortium (MCC)